

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/026081 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 487/08 (2006.01)
C07D 405/14 (2006.01) A61P 29/00 (2006.01)
C07D 471/04 (2006.01) A61P 35/00 (2006.01)
C07D 471/10 (2006.01) A61K 31/517 (2006.01)

(21) International Application Number:

PCT/US2023/028955

(22) International Filing Date:

28 July 2023 (28.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/393,522 29 July 2022 (29.07.2022) US
63/420,307 28 October 2022 (28.10.2022) US
63/443,170 03 February 2023 (03.02.2023) US

(71) Applicant: **RIBON THERAPEUTICS, INC.** [US/US];
35 Cambridgepark Drive, Suite 300, Cambridge, Massachu-
setts 02140 (US).

(72) Inventors: **PERL, Nicholas Robert**; 35 Cambridgepark
Drive, Suite 300, Cambridge, Massachusetts 02140 (US).
KUNTZ, Kevin Wayne; 35 Cambridgepark Drive, Suite
300, Cambridge, Massachusetts 02140 (US). **DOWNING,**

Jennifer; 35 Cambridgepark Drive, Suite 300, Cambridge,
Massachusetts 02140 (US).

(74) Agent: **SEARS, Justin Edward** et al.; Fish & Richardson
P.C., PO Box 1022, Minneapolis, Minnesota 55440 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY





FIG. 1



(57) Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*